文章摘要
韩 刚,曹 羽,张 云,张言言,张 旭,胡 建,龚航军,刘宁宁,贾 茹.METTL3介导EZH2 m6A修饰在结直肠癌5-氟尿嘧啶耐药中的作用机制研究[J].,2022,(3):418-422
METTL3介导EZH2 m6A修饰在结直肠癌5-氟尿嘧啶耐药中的作用机制研究
METTL3 Contributes to 5-Fu Resistance via EZH2 m6A Modification in Colorectal Cancer
投稿时间:2021-04-28  修订日期:2021-05-24
DOI:10.13241/j.cnki.pmb.2022.03.004
中文关键词: RNA甲基化  METTL3  EZH2  结直肠癌  5-氟尿嘧啶  耐药
英文关键词: RNA methylation  METTL3  EZH2  Colorectal cancer  5-FU  Resistance
基金项目:上海中医药大学预算内项目资助(2019LK019);国家自然科学基金面上项目(81973651)
作者单位E-mail
韩 刚 上海中医药大学附属曙光医院 胃肠外科 上海 201203 hanhang883@126.com 
曹 羽 上海中医药大学附属曙光医院 胃肠外科 上海 201203  
张 云 上海中医药大学附属曙光医院 胃肠外科 上海 201203  
张言言 上海中医药大学附属曙光医院 胃肠外科 上海 201203  
张 旭 上海中医药大学附属曙光医院 胃肠外科 上海 201203  
胡 建 上海中医药大学附属曙光医院 胃肠外科 上海 201203  
龚航军 上海中医药大学附属曙光医院 胃肠外科 上海 201203  
刘宁宁 上海中医药大学附属曙光医院 肿瘤科 上海 201203  
贾 茹 上海中医药大学附属曙光医院 肿瘤科 上海 201203  
摘要点击次数: 919
全文下载次数: 544
中文摘要:
      摘要 目的:探讨甲基转移酶样蛋白3(METTL3)在5-氟尿嘧啶耐药中的作用机制。方法:大剂量间歇诱导法建立5-FU耐药细胞株。在耐药组细胞中分别敲减METTL3及EZH2抑制GSK343处理。qPCR及Western blot检测METTL3和EZH2表达。CCK-8检测各组细胞增殖情况。m6A甲基化RNA免疫沉淀技术分析EZH2 mRNA m6A修饰修饰情况。结果:各药物浓度处理下的耐药组细胞增殖活性与未处理细胞无显著差异(P>0.05)而原代细胞组肠癌细胞较未处理细胞在0.5-10 μg/mL处理下细胞增殖活性显著减低(P<0.01)。耐药组细胞与原代细胞组相比,METTL3及EZH2表达水平显著升高(P<0.01)。耐药组细胞METTL3敲减后或GSK343处理后,在0.5 μg/mL-10 μg/mL浓度间下的细胞增殖活性与0 μg/mL处理细胞增殖活性相比显著减低(P<0.05)。耐药组细胞METTL3敲减细胞的EZH2表达与对照细胞比,显著下调(P<0.01)。m6A甲基化RNA免疫沉淀实验显示耐药组细胞METTL3敲减细胞的EZH2 mRNA m6A修饰水平(m6A富集度为6361.95±67.47%),较未敲减细胞修饰水平(396.30±57.74)显著减低(P<0.01)。结论:METTL3在肠癌细胞5-FU耐药抵抗中起到关键作用,靶向抑制METTL3有望成为缓解肠癌耐药的重要分子靶点。
英文摘要:
      ABSTRACT Objective: To investigate the role of METTL3 in 5-fluorouracil resistance. Methods: High-dose intermittent induction method was used to establish 5-FU resistant cell lines. Knockdown of METTL3 or EZH2 inhibitor GSK343 treatment were performed in drug-resistant cells. qPCR and Western blot were used to detect the expression of METTL3 and EZH2. CCK-8 was used to detect cell proliferation in each group. The m6A methylated RNA immunoprecipitation was used to analyze the modification of EZH2 mRNA m6A. Results: There was no significant difference in the proliferation activity of the drug-resistant group and the untreated cells under the treatment of various drug concentrations (P>0.05), however the primary cell group of intestinal cancer cells had a significant decreased proliferation activity compared to untreated cells under 0.5-10 μg/mL. Compared with the primary cell group, the expression levels of METTL3 and EZH2 in the drug-resistant group were significantly higher (P<0.01). After knockdown of METL3 or GSK343 in the drug-resistant group, the proliferation activity of cells at a concentration of 0.5 μg/mL-10 μg/mL was significantly lower than that of cells treated with 0 μg/mL (P<0.05). Compared with the control cells, the expression of EZH2 in the METTL3 knockdown cells of the drug resistance group was significantly down-regulated(P<0.01). The m6A methylated RNA immunoprecipitation experiment showed that the EZH2 mRNA m6A modification level (m6A enrichment of 6361.95±67.47%) of the METL3 knockdown cells in the drug-resistant group was significantly lower than that of the non-knockdown cells (396.30±57.74)(P<0.01). Conclusion: METL3 plays a key role in 5-FU resistance of colorectal cancer cells. Targeted inhibition of METL3 is expected to become an important molecular target for alleviating resistance of colorectal cancer.
查看全文   查看/发表评论  下载PDF阅读器
关闭